Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SNS-595 in Advanced Small Cell Lung Cancer
NCT00298896Phase 2Completed
- Sponsor
- Sunesis Pharmaceuticals, Inc.
- Start
- Feb 2006
- Primary completion
- Aug 2007
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
Phase 2, open-label, single-arm trial of vosaroxin in small cell lung cancer (SCLC), sponsored by Sunesis Pharmaceuticals, Inc. Primary endpoint: Objective Response Rate at 6 months. Started Feb 2006; status: completed.
02
Drugs
vosaroxin
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on NCT00298896.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00298896.